All In Biotech

NDA 021980 · Alcon Labs INC

Fluorescite

Fluorescein Sodium · Intravenous · Diagnostic Dye

Priority review

Last checked: Nov 19, 2026Latest source record: Jun 10, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2006

Mar 28, 2006

Approved uses

1

Original approval plus efficacy supplements

Registered trials

106

19 Phase 3, 6 recruiting

FAERS reports

564

539 serious, 34 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 6, 2026.

FLUORESCITE ® Injection 10% is indicated in diagnostic fluorescein angiography or angioscopy of the retina and iris vasculature. FLUORESCITE ® Injection 10% is indicated in diagnostic fluorescein angiography or angioscopy of the retina and iris vasculature. (1)

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 28, 2006 Original approval · Type 5 - New Formulation or New Manufacturer · priority review ReviewLabelLetter
1 products under this application
  • FLUORESCITE · FLUORESCEIN SODIUM EQ 500MG BASE/5ML (EQ 100MG BASE/ML) · INJECTABLE, INTRAVENOUS · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Fluorescein" as an intervention, any sponsor and status, largest first.

All 106 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • nausea72
  • anaphylactic shock56
  • pruritus54
  • dyspnoea52
  • dizziness50
  • vomiting49
  • rash47
  • loss of consciousness45
  • visual acuity reduced37
  • chest discomfort31
  • urticaria31
  • asthenia25

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20047
200510
20067
20077
200814
200976
201023
201112
201215
201311
201426
201524
201630
201720
201822
201935
202056
202122
202228
202331
202439
202534
202615

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,795 on PubMed

Sponsor: Alcon Labs INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.